ADA2
Basic information
Region (hg38): 22:17178790-17258235
Previous symbols: [ "IDGFL", "CECR1" ]
Links
Phenotypes
GenCC
Source:
- vasculitis due to ADA2 deficiency (Strong), mode of inheritance: AR
- Sneddon syndrome (Moderate), mode of inheritance: AR
- polyarteritis nodosa (Moderate), mode of inheritance: AR
- Diamond-Blackfan anemia (Supportive), mode of inheritance: AD
- Sneddon syndrome (Supportive), mode of inheritance: AD
- vasculitis due to ADA2 deficiency (Supportive), mode of inheritance: AR
- vasculitis due to ADA2 deficiency (Strong), mode of inheritance: AR
- deficiency of adenosine deaminase 2 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome; Sneddon syndrome | AR | Allergy/Immunology/Infectious | Among other manifestations, individuals have been described as presenting with hypogammaglobulinemia, as well as recurrent bacterial and viral infections, and immunosuppressive treatment has been described as beneficial, though other manifestations have been described as recalcitrant to these types of therapies; Medical management (eg, with TNF inhibitor) has been described as beneficial. | Allergy/Immunology/Infectious; Cardiovascular; Dermatologic | 12804991; 24552284; 24552285; 25075844; 25075847 |
ClinVar
This is a list of variants' phenotypes submitted to
- Vasculitis due to ADA2 deficiency (34 variants)
- not provided (8 variants)
- Vasculitis due to ADA2 deficiency;Sneddon syndrome (3 variants)
- ADA2-related disorder (3 variants)
- Sneddon syndrome (3 variants)
- Sneddon syndrome;Vasculitis due to ADA2 deficiency (2 variants)
- Autoinflammatory syndrome (1 variants)
- See cases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ADA2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 77 | 83 | ||||
missense | 13 | 203 | 230 | |||
nonsense | 9 | |||||
start loss | 3 | |||||
frameshift | 12 | 16 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 10 | |||||
splice region | 1 | 10 | 19 | 1 | 31 | |
non coding | 49 | 34 | 85 | |||
Total | 36 | 25 | 208 | 130 | 38 |
Highest pathogenic variant AF is 0.000171
Variants in ADA2
This is a list of pathogenic ClinVar variants found in the ADA2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
22-17181488-T-G | Vasculitis due to ADA2 deficiency • Sneddon syndrome;Vasculitis due to ADA2 deficiency | Uncertain significance (May 27, 2022) | ||
22-17181497-C-T | Vasculitis due to ADA2 deficiency | Uncertain significance (Aug 17, 2022) | ||
22-17181506-T-C | Vasculitis due to ADA2 deficiency | Uncertain significance (Jul 30, 2022) | ||
22-17181518-A-G | Uncertain significance (Jun 16, 2016) | |||
22-17181522-C-T | Vasculitis due to ADA2 deficiency | Likely benign (Jan 01, 2023) | ||
22-17181545-T-C | Vasculitis due to ADA2 deficiency • ADA2-related disorder | Uncertain significance (May 09, 2023) | ||
22-17181546-A-ATT | Vasculitis due to ADA2 deficiency | Likely pathogenic (Jan 18, 2024) | ||
22-17181552-C-G | Vasculitis due to ADA2 deficiency • not specified • Autoinflammatory syndrome | Conflicting classifications of pathogenicity (Dec 28, 2023) | ||
22-17181554-C-G | Vasculitis due to ADA2 deficiency • Autoinflammatory syndrome • Vasculitis due to ADA2 deficiency;Sneddon syndrome | Uncertain significance (Sep 01, 2022) | ||
22-17181554-C-T | Autoinflammatory syndrome | Uncertain significance (Jul 23, 2021) | ||
22-17181564-C-T | Vasculitis due to ADA2 deficiency | Likely benign (Apr 26, 2022) | ||
22-17181567-G-C | Vasculitis due to ADA2 deficiency | Likely benign (Sep 29, 2022) | ||
22-17181567-GGTACT-G | Vasculitis due to ADA2 deficiency | Pathogenic (May 08, 2023) | ||
22-17181572-T-G | Vasculitis due to ADA2 deficiency | Likely pathogenic (Mar 25, 2024) | ||
22-17181574-T-C | Vasculitis due to ADA2 deficiency | Uncertain significance (Oct 24, 2022) | ||
22-17181576-C-A | Vasculitis due to ADA2 deficiency | Uncertain significance (Jan 15, 2024) | ||
22-17181582-G-C | Vasculitis due to ADA2 deficiency | Likely benign (Dec 11, 2023) | ||
22-17181583-GA-G | Vasculitis due to ADA2 deficiency | Likely benign (Aug 07, 2023) | ||
22-17181586-G-T | Vasculitis due to ADA2 deficiency | Likely benign (Oct 13, 2021) | ||
22-17181589-G-A | Vasculitis due to ADA2 deficiency | Likely benign (Oct 28, 2021) | ||
22-17181592-G-A | Vasculitis due to ADA2 deficiency | Likely benign (Mar 10, 2022) | ||
22-17181594-G-A | Vasculitis due to ADA2 deficiency | Likely benign (Sep 02, 2022) | ||
22-17181701-C-G | not specified | Benign (Nov 12, 2023) | ||
22-17181789-C-T | not specified | Benign (Nov 12, 2023) | ||
22-17181800-G-C | Vasculitis due to ADA2 deficiency | Likely benign (Dec 04, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ADA2 | protein_coding | protein_coding | ENST00000399839 | 9 | 42686 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.14e-8 | 0.736 | 125667 | 0 | 80 | 125747 | 0.000318 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.357 | 280 | 297 | 0.942 | 0.0000159 | 3403 |
Missense in Polyphen | 87 | 90.478 | 0.96156 | 1101 | ||
Synonymous | 0.367 | 108 | 113 | 0.956 | 0.00000657 | 959 |
Loss of Function | 1.32 | 14 | 20.5 | 0.684 | 0.00000104 | 239 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000793 | 0.000793 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000464 | 0.0000462 |
European (Non-Finnish) | 0.000388 | 0.000387 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000229 | 0.000229 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Adenosine deaminase that may contribute to the degradation of extracellular adenosine, a signaling molecule that controls a variety of cellular responses. Requires elevated adenosine levels for optimal enzyme activity. Binds to cell surfaces via proteoglycans and may play a role in the regulation of cell proliferation and differentiation, independently of its enzyme activity. {ECO:0000269|PubMed:20147294, ECO:0000269|PubMed:20453107}.;
- Disease
- DISEASE: Polyarteritis nodosa (PAN) [MIM:615688]: A systemic necrotizing vasculitis that affects medium and small arteries. The ensuing tissue ischemia can affect any organ, including the skin, musculoskeletal system, kidneys, gastrointestinal tract, and the cardiovascular and nervous systems. Organ involvement and disease severity are highly variable. Clinical features include recurrent ischemic stroke affecting the small vessels of the brain and resulting in neurologic dysfunction, recurrent fever, myalgias, livedoid rash, gastrointestinal pain and hepatosplenomegaly. {ECO:0000269|PubMed:24552284, ECO:0000269|PubMed:24552285}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Sneddon syndrome (SNDDS) [MIM:182410]: A systemic non- inflammatory thrombotic vasculopathy characterized by the association of livedo racemosa, and in some cases livedo reticularis, with cerebrovascular disease. Livedo racemosa is a persistent net-like violaceous-cyanotic, mottled discoloration of the skin affecting the legs, the arms, the buttocks and the trunk; livedo reticularis is limited to the extremities and is visible only in the cold. Cerebrovascular features include recurrent transient ischemic attacks, infarcts, and rarely spinal strokes or intracranial or subarachnoid hemorrhages. Headache and vertigo may precede the onset of livedo racemosa and cerebrovascular manifestations by several years. Rare neurologic symptoms include seizures, chorea, or myelopathies. {ECO:0000269|PubMed:25075847}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Purine metabolism - Homo sapiens (human);Neutrophil degranulation;Surfactant metabolism;Metabolism of proteins;Innate Immune System;Immune System
(Consensus)
Recessive Scores
- pRec
- 0.0931
Intolerance Scores
- loftool
- rvis_EVS
- -0.35
- rvis_percentile_EVS
- 29.43
Haploinsufficiency Scores
- pHI
- 0.308
- hipred
- N
- hipred_score
- 0.187
- ghis
- 0.505
Essentials
- essential_gene_CRISPR
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- gene_indispensability_score
Zebrafish Information Network
- Gene name
- ada2b
- Affected structure
- neutrophil
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- adenosine catabolic process;multicellular organism development;regulation of signaling receptor activity;neutrophil degranulation;cellular protein metabolic process;inosine biosynthetic process
- Cellular component
- extracellular region;extracellular space;azurophil granule lumen
- Molecular function
- adenosine deaminase activity;growth factor activity;heparin binding;zinc ion binding;adenosine receptor binding;protein homodimerization activity;proteoglycan binding